Glioma Response to IDH Inhibition: Real-World Experience.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Treatment of IDH mutated non-enhancing grade 2 and 3 diffuse gliomas with ivosidenib leads to reduction of tumor size when assessed via volumetric MRI. IDH inhibition has a therapeutic benefit in patients with these tumors.

Keyphrases

low grade
high grade
wild type
magnetic resonance imaging
contrast enhanced
diffusion weighted imaging
replacement therapy
smoking cessation